487 | Humans |
239 | Animals |
219 | Female |
210 | Male |
140 | Chloroquine (pharmacology) |
119 | Mice |
99 | Chloroquine (therapeutic use) |
99 | Cell Line, Tumor |
96 | Autophagy (drug effects) |
92 | Adult |
83 | Middle Aged |
74 | Lung Neoplasms (pathology) |
70 | Lung Neoplasms (drug therapy) |
61 | Hydroxychloroquine (therapeutic use) |
57 | Rats |
54 | Lung (metabolism) |
54 | Apoptosis (drug effects) |
50 | Lung Neoplasms (metabolism) |
50 | Aged |
48 | Child |
47 | Treatment Outcome |
47 | Cells, Cultured |
44 | Cell Proliferation (drug effects) |
42 | Lung (pathology) |
42 | Lung (drug effects) |
41 | Cell Line |
41 | Antineoplastic Agents (pharmacology) |
39 | Cell Survival (drug effects) |
38 | Lung Diseases (drug therapy) |
37 | Carcinoma, Non-Small-Cell Lung (pathology) |
36 | Sarcoidosis (drug therapy) |
33 | Mice, Inbred BALB C |
32 | Infant |
32 | Dose-Response Relationship, Drug |
32 | Carcinoma, Non-Small-Cell Lung (drug therapy) |
31 | Lung Diseases, Interstitial (drug therapy) |
31 | Adolescent |
30 | Signal Transduction (drug effects) |
28 | Drug Therapy, Combination |
28 | Antimalarials (pharmacology) |
27 | Time Factors |
27 | Mice, Nude |
27 | Immunosuppressive Agents (therapeutic use) |
27 | A549 Cells |
26 | Xenograft Model Antitumor Assays |
26 | Tomography, X-Ray Computed |
26 | Retrospective Studies |
26 | Lung Neoplasms (genetics) |
26 | Disease Models, Animal |
26 | Child, Preschool |
24 | Microtubule-Associated Proteins (metabolism) |
24 | Drug Synergism |
24 | Antirheumatic Agents (therapeutic use) |
23 | Diagnosis, Differential |
22 | Radiography |
21 | Plasmodium falciparum (drug effects) |
21 | Mutation |
21 | Mice, Inbred C57BL |
21 | Follow-Up Studies |
21 | Chloroquine (administration & dosage) |
21 | Adrenal Cortex Hormones (therapeutic use) |
20 | Prognosis |
20 | Glucocorticoids (therapeutic use) |
20 | Antineoplastic Agents (therapeutic use) |
19 | Tumor Cells, Cultured |
19 | Lysosomes (metabolism) |
19 | Carcinoma, Non-Small-Cell Lung (metabolism) |
19 | Biopsy |
18 | TOR Serine-Threonine Kinases (metabolism) |
18 | Signal Transduction |
18 | Lung Diseases (diagnosis) |
18 | Hydrogen-Ion Concentration |
18 | Autophagy |
17 | Reactive Oxygen Species (metabolism) |
17 | Proto-Oncogene Proteins c-akt (metabolism) |
17 | Lung (cytology) |
17 | Liver (metabolism) |
17 | Cyclophosphamide (therapeutic use) |
16 | Methotrexate (therapeutic use) |
16 | Lupus Erythematosus, Systemic (complications) |
16 | Lung Diseases, Interstitial (diagnosis) |
16 | Infant, Newborn |
16 | Chloroquine |
16 | Chloroquine (adverse effects) |
15 | Protein Kinase Inhibitors (pharmacology) |
15 | Prednisone (therapeutic use) |
15 | Prednisolone (therapeutic use) |
15 | Lung Diseases, Interstitial (etiology) |
15 | Hydroxychloroquine (administration & dosage) |
15 | Chloroquine (metabolism) |
15 | Carcinoma, Non-Small-Cell Lung (genetics) |
14 | Respiratory Function Tests |
14 | Molecular Structure |
14 | Microtubule-Associated Proteins (genetics) |
14 | Lung (diagnostic imaging) |
14 | In Vitro Techniques |
14 | Hemosiderosis (drug therapy) |
14 | Drug Resistance, Neoplasm (drug effects) |
14 | Azathioprine (therapeutic use) |
13 | Receptors, G-Protein-Coupled (metabolism) |
13 | Rats, Sprague-Dawley |
13 | Malaria (drug therapy) |
13 | Lysosomes (drug effects) |
13 | Lupus Erythematosus, Systemic (drug therapy) |
13 | Lung Diseases, Interstitial (therapy) |
13 | Lung Diseases, Interstitial (genetics) |
13 | Kidney (metabolism) |
13 | ErbB Receptors (genetics) |
13 | Blotting, Western |
13 | Autophagy (physiology) |
12 | Structure-Activity Relationship |
12 | Phosphorylation (drug effects) |
12 | Gene Expression Regulation, Neoplastic (drug effects) |
12 | Fibroblasts (drug effects) |
12 | Chronic Disease |
12 | Arthritis, Rheumatoid (drug therapy) |
12 | Antimalarials (therapeutic use) |
12 | Anti-Inflammatory Agents (therapeutic use) |
11 | Tissue Distribution |
11 | RNA, Messenger (metabolism) |
11 | Plant Extracts (pharmacology) |
11 | Phospholipids (metabolism) |
11 | Kinetics |
11 | Hydroxychloroquine (adverse effects) |
11 | Chloroquine (chemistry) |
11 | Antineoplastic Agents, Phytogenic (pharmacology) |
11 | Antimalarials (chemistry) |
10 | Sarcoidosis (diagnosis) |
10 | Receptors, G-Protein-Coupled (agonists) |
10 | Pulmonary Fibrosis (drug therapy) |
10 | Myocardium (metabolism) |
10 | Methylprednisolone (therapeutic use) |
10 | Lung Diseases (etiology) |
10 | Hydroxychloroquine (pharmacology) |
10 | Guinea Pigs |
10 | Fibroblasts (metabolism) |
10 | ErbB Receptors (antagonists & inhibitors) |
10 | Autophagy (genetics) |
10 | Antineoplastic Agents (chemistry) |
10 | Antineoplastic Agents (administration & dosage) |
10 | Adenine (analogs & derivatives) |
9 | Young Adult |
9 | Spleen (metabolism) |
9 | Sjogren's Syndrome (complications) |
9 | Rabbits |
9 | RNA Interference |
9 | Pulmonary Surfactant-Associated Protein C (genetics) |
9 | Muscle, Smooth (drug effects) |
9 | Lung Diseases, Interstitial (physiopathology) |
9 | Lung Diseases, Interstitial (complications) |
9 | Lung Diseases (pathology) |
9 | Drug Resistance |
9 | Cell Cycle (drug effects) |
9 | Brain (metabolism) |
9 | Apoptosis |
9 | Adenocarcinoma (drug therapy) |
9 | Adenine (pharmacology) |
8 | TOR Serine-Threonine Kinases (antagonists & inhibitors) |
8 | Syndrome |
8 | Sarcoidosis, Pulmonary (drug therapy) |
8 | Rats, Inbred Strains |
8 | Radiography, Thoracic |
8 | Quinazolines (pharmacology) |
8 | Pregnancy |
8 | Plasmodium (drug effects) |
8 | Phosphorylation |
8 | Neoplasm Metastasis |
8 | Mitochondria (drug effects) |
8 | Microscopy, Electron, Transmission |
8 | Membrane Potential, Mitochondrial (drug effects) |
8 | Lung Neoplasms (secondary) |
8 | Lung Diseases, Interstitial (pathology) |
8 | Lung Diseases (complications) |
8 | Lung (physiology) |
8 | Immunosuppressive Agents (adverse effects) |
8 | Hemosiderosis (diagnosis) |
8 | Gene Knockdown Techniques |
8 | Fatal Outcome |
8 | ErbB Receptors (metabolism) |
8 | Epithelial Cells (metabolism) |
8 | Drug Screening Assays, Antitumor |
8 | Disease Progression |
8 | Cisplatin (pharmacology) |
8 | Cell Survival |
8 | Cell Movement (drug effects) |
8 | Caspase 3 (metabolism) |
8 | Arthritis, Rheumatoid (complications) |
8 | Anti-Bacterial Agents (therapeutic use) |
7 | Virus Replication (drug effects) |
7 | Tumor Burden (drug effects) |
7 | Sjogren's Syndrome (drug therapy) |
7 | RNA, Messenger (genetics) |
7 | Pulmonary Fibrosis (pathology) |
7 | Phosphatidylinositol 3-Kinases (metabolism) |
7 | Phagosomes (metabolism) |
7 | Neoplasm Transplantation |
7 | Myocytes, Smooth Muscle (metabolism) |
7 | Myocytes, Smooth Muscle (drug effects) |
7 | Mitochondria (metabolism) |
7 | Microscopy, Electron |
7 | Lung Neoplasms (immunology) |
7 | Lung Diseases |
7 | Lung Diseases, Parasitic |
7 | Lung (analysis) |
7 | Inhibitory Concentration 50 |
7 | Hemorrhage (etiology) |
7 | Gene Expression Regulation, Neoplastic |
7 | Flow Cytometry |
7 | Enzyme Inhibitors (pharmacology) |
7 | Emetine (therapeutic use) |
7 | Drug Resistance, Neoplasm |
7 | Drug Resistance, Neoplasm (genetics) |
7 | Chloroquine (toxicity) |
7 | Chloroquine (analogs & derivatives) |
7 | Case-Control Studies |
7 | Beclin-1 (metabolism) |
7 | Asthma (drug therapy) |
7 | Apoptosis Regulatory Proteins (metabolism) |
7 | Antineoplastic Combined Chemotherapy Protocols (pharmacology) |
7 | Aged, 80 and over |
7 | Acute Disease |
6 | Tumor Suppressor Protein p53 (metabolism) |
6 | Transfection |
6 | Severity of Illness Index |
6 | Sarcoidosis (pathology) |
6 | Rats, Wistar |
6 | Radionuclide Imaging |
6 | Proto-Oncogene Proteins c-akt (antagonists & inhibitors) |
6 | Muscles (metabolism) |
6 | Muscle Relaxation (drug effects) |
6 | Microscopy, Fluorescence |
6 | Membrane Proteins (metabolism) |
6 | Macrophages (drug effects) |
6 | Macrolides (pharmacology) |
6 | Lupus Erythematosus, Systemic (diagnosis) |
6 | Lung |
6 | Lung Neoplasms |
6 | Lung Neoplasms (therapy) |
6 | Lung Diseases, Interstitial (diagnostic imaging) |
6 | Lung Diseases (therapy) |
6 | Lung (physiopathology) |
6 | Lung (embryology) |
6 | Lipidoses (chemically induced) |
6 | Indoles (pharmacology) |
6 | Incidence |
6 | Immunosuppressive Agents (administration & dosage) |
6 | Immunohistochemistry |
6 | HeLa Cells |
6 | HCT116 Cells |
6 | Gene Transfer Techniques |
6 | Gene Expression Regulation (drug effects) |
6 | Gefitinib |
6 | Epithelial Cells (drug effects) |
6 | Dysentery, Amebic |
6 | Drug Evaluation, Preclinical |
6 | Drug Administration Schedule |
6 | Dogs |
6 | Dermatomyositis (drug therapy) |
6 | Clinical Trials as Topic |
6 | Chloroquine (pharmacokinetics) |
6 | Chloroquine (blood) |
6 | Bronchodilator Agents (pharmacology) |
6 | Beclin-1 (genetics) |
6 | Apoptosis (genetics) |
6 | Antiviral Agents (pharmacology) |
6 | Antirheumatic Agents (adverse effects) |
6 | Antimalarials (isolation & purification) |
6 | Antimalarials (chemical synthesis) |
6 | Antimalarials (adverse effects) |
6 | Anti-Inflammatory Agents (administration & dosage) |
6 | Age Factors |
6 | Adenocarcinoma of Lung |
6 | Adenocarcinoma (pathology) |
6 | Adaptor Proteins, Signal Transducing (metabolism) |
6 | AMP-Activated Protein Kinases (metabolism) |
5 | Survival Analysis |
5 | Sirolimus (pharmacology) |
5 | Sex Factors |
5 | Rituximab (therapeutic use) |
5 | Risk Factors |
5 | Reverse Transcriptase Polymerase Chain Reaction |
5 | Respiratory Distress Syndrome, Newborn (genetics) |
5 | Respiration, Artificial |
5 | Recurrence |
5 | RNA, Small Interfering (genetics) |
5 | Quinolines (pharmacology) |
5 | Quinine (therapeutic use) |
5 | Pyridines (pharmacology) |
5 | Pulmonary Fibrosis (diagnosis) |
5 | Protein Binding |
5 | Prevalence |
5 | Prednisolone (administration & dosage) |
5 | Plants, Medicinal (chemistry) |
5 | Plant Extracts (chemistry) |
5 | Phenotype |
5 | Phagosomes (drug effects) |
5 | Penicillamine (therapeutic use) |
5 | Oxygen Inhalation Therapy |
5 | Organ Size |
5 | Neoplasms (pathology) |
5 | Neoplasms (drug therapy) |
5 | NF-kappa B (metabolism) |
5 | Mycophenolic Acid (therapeutic use) |
5 | Muscle, Smooth (physiology) |
5 | Muscle Relaxation (physiology) |
5 | Models, Biological |
5 | Mice, Knockout |
5 | Metronidazole (therapeutic use) |
5 | MAP Kinase Signaling System (drug effects) |
5 | Lysosomes (enzymology) |
5 | Lung Diseases, Parasitic (drug therapy) |
5 | Lung (ultrastructure) |
5 | Lung (microbiology) |
5 | Lung (immunology) |
5 | Lung (enzymology) |
5 | Lung (chemistry) |
5 | Liver Abscess |
5 | Liver Abscess, Amebic |
5 | Liver Abscess, Amebic (complications) |
5 | Liver (drug effects) |
5 | Inflammation (pathology) |
5 | Hydroxychloroquine (metabolism) |
5 | HEK293 Cells |
5 | Enzyme-Linked Immunosorbent Assay |
5 | Enzyme Inhibitors (therapeutic use) |
5 | Endothelium, Vascular (metabolism) |
5 | Emetine |
5 | Dyspnea (etiology) |
5 | Drug Interactions |
5 | Drug Combinations |
5 | Down-Regulation (drug effects) |
5 | Dermatomyositis (diagnosis) |
5 | DNA (chemistry) |
5 | Cyclophosphamide (administration & dosage) |
5 | Chloroquine (analysis) |
5 | Cell Proliferation |
5 | Body Weight |
5 | Binding Sites |
5 | Beclin-1 |
5 | Anti-Bacterial Agents (pharmacology) |
5 | Amebiasis |
5 | Administration, Inhalation |
5 | Adenocarcinoma (metabolism) |
4 | Tumor Necrosis Factor-alpha (antagonists & inhibitors) |
4 | Tomography, X-Ray Computed (methods) |
4 | Toll-Like Receptor 9 (metabolism) |
4 | Tandem Mass Spectrometry (methods) |
4 | Swine |
4 | Survival Rate |
4 | Sirolimus (therapeutic use) |
4 | Signal Transduction (physiology) |
4 | Scleroderma, Systemic (complications) |
4 | Sarcoidosis (physiopathology) |
4 | Sarcoidosis (diagnostic imaging) |
4 | Sarcoidosis (complications) |
4 | STAT3 Transcription Factor (metabolism) |
4 | Risk Assessment |
4 | Respiratory System (metabolism) |
4 | Respiratory Distress Syndrome, Newborn (etiology) |
4 | Randomized Controlled Trials as Topic |
4 | Radiation Tolerance (drug effects) |
4 | Quercetin (pharmacology) |
4 | Pulmonary Alveoli (metabolism) |
4 | Proto-Oncogene Proteins c-bcl-2 (metabolism) |
4 | Plasmids |
4 | Phospholipases A2 |
4 | Phosphoinositide-3 Kinase Inhibitors |
4 | Phagosomes (ultrastructure) |
4 | Peptides (pharmacology) |
4 | Oligodeoxyribonucleotides (pharmacology) |
4 | Mutation (genetics) |
4 | Muscle Contraction (drug effects) |
4 | Molecular Weight |
4 | Mice, Inbred DBA |
4 | Membrane Proteins (genetics) |
4 | Macrophages (pathology) |
4 | Macrophages (metabolism) |
4 | Lysosomes (pathology) |
4 | Lymphangioleiomyomatosis (drug therapy) |
4 | Lupus Erythematosus, Systemic (physiopathology) |
4 | Lung Neoplasms (enzymology) |
4 | Lung Diseases, Parasitic (diagnosis) |
4 | Lung Diseases, Interstitial (epidemiology) |
4 | Lung Diseases, Interstitial (chemically induced) |
4 | Lung Diseases (physiopathology) |
4 | Lung Diseases (diagnostic imaging) |
4 | Lung Abscess |
4 | Lung (virology) |
4 | Lung (blood supply) |
4 | Liver Abscess, Amebic (drug therapy) |
4 | Liver Abscess, Amebic (diagnosis) |
4 | Liver (pathology) |
4 | Ligands |
4 | Injections, Intravenous |
4 | Infusions, Intravenous |
4 | Immunologic Factors (pharmacology) |
4 | Immunoblotting |
4 | Imidazoles (pharmacology) |
4 | Hydroxychloroquine (blood) |
4 | Hemorrhage (diagnosis) |
4 | Heart (drug effects) |
4 | Gene Expression |
4 | Gene Expression Regulation |
4 | Fungal Proteins (pharmacology) |
4 | Eye (metabolism) |
4 | Endothelial Cells (metabolism) |
4 | Endocytosis (drug effects) |
4 | Down-Regulation |
4 | Dermatomyositis (complications) |
4 | DNA Damage |
4 | Cytokines (metabolism) |
4 | Cross-Sectional Studies |
4 | Cricetulus |
4 | Cricetinae |
4 | Combined Modality Therapy |
4 | Collagen (metabolism) |
4 | Chromatography, High Pressure Liquid |
4 | Cholesterol Esters (metabolism) |
4 | Cholesterol (metabolism) |
4 | Chloroquine (poisoning) |
4 | Chick Embryo |
4 | Cell Cycle Checkpoints (drug effects) |
4 | Caspases (metabolism) |
4 | Calcium Signaling (drug effects) |
4 | Calcium Channel Blockers (pharmacology) |
4 | Bronchoalveolar Lavage Fluid (chemistry) |
4 | Blood Pressure (drug effects) |
4 | Autoimmune Diseases (drug therapy) |
4 | Asthma (metabolism) |
4 | Aspirin (pharmacology) |
4 | Apoptosis Regulatory Proteins (genetics) |
4 | Apoptosis (physiology) |
4 | Antirheumatic Agents (administration & dosage) |
4 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
4 | Antimalarials (administration & dosage) |
4 | Ammonium Chloride (pharmacology) |
4 | Aminoquinolines (pharmacology) |
4 | Adrenergic beta-Agonists (pharmacology) |
4 | Adrenal Cortex Hormones (administration & dosage) |
4 | Administration, Oral |
4 | ATP-Binding Cassette Transporters (genetics) |
3 | src-Family Kinases (metabolism) |
3 | Vasculitis (drug therapy) |
3 | Vascular Resistance |
3 | Vascular Resistance (drug effects) |
3 | Vacuoles (metabolism) |
3 | Up-Regulation (drug effects) |
3 | Tumor Necrosis Factor-alpha (metabolism) |
3 | Tuberculosis, Pulmonary (diagnosis) |
3 | Triterpenes (pharmacology) |
3 | Trachea (physiology) |
3 | Toxicology |
3 | Toll-Like Receptor 9 (physiology) |
3 | Toll-Like Receptor 9 (genetics) |
3 | Taste |
3 | Taste (physiology) |
3 | Taste (drug effects) |
3 | TOR Serine-Threonine Kinases (genetics) |
3 | Surveys and Questionnaires |
3 | Stomach (analysis) |
3 | Stereoisomerism |
3 | Spectrophotometry |
3 | Species Specificity |
3 | Skin (pathology) |
3 | Skin (metabolism) |
3 | Sjogren's Syndrome (diagnosis) |
3 | Siblings |
3 | Serotonin (analysis) |
3 | Sequestosome-1 Protein |
3 | Scleroderma, Systemic (drug therapy) |
3 | Respiratory Function Tests (methods) |
3 | Research |
3 | Reproducibility of Results |
3 | Reperfusion Injury (metabolism) |
3 | Remission Induction |
3 | Receptors, G-Protein-Coupled (genetics) |
3 | Radiation-Sensitizing Agents (pharmacology) |
3 | RNA, Small Interfering (metabolism) |
3 | Quinolines (therapeutic use) |
3 | Quinacrine (pharmacology) |
3 | Quaternary Ammonium Compounds (pharmacology) |
3 | Pyrimidines (pharmacology) |
3 | Pulmonary Fibrosis (therapy) |
3 | Pulmonary Fibrosis (chemically induced) |
3 | Pulmonary Edema (etiology) |
3 | Proto-Oncogene Proteins c-akt (genetics) |
3 | Proteolysis |
3 | Protein Processing, Post-Translational (drug effects) |
3 | Protein Kinase Inhibitors (therapeutic use) |
3 | Prednisone (administration & dosage) |
3 | Poly(ADP-ribose) Polymerases (metabolism) |
3 | Poly I-C (pharmacology) |
3 | Plasmodium falciparum |
3 | Plasmodium falciparum (growth & development) |
3 | Plant Extracts (therapeutic use) |
3 | Piperazines (pharmacology) |
3 | Phospholipases A (antagonists & inhibitors) |
3 | Phenanthrenes (pharmacology) |
3 | Pharmacology |
3 | Parasitic Sensitivity Tests |